The information collection deals with
FDA's patent term restoration regulations on due diligence
petitions for regulatory review period revision. When a patented
product must receive FDA approval before marketing is permitted,
the Patent and Trademark Office (PTO) may add a portion of FDA's
review time to the term of a patent. Petitioners may request
reductions in the regulatory review time if FDA marketing approval
was not pursued with ``due diligence.''
US Code:
35
USC 156 Name of Law: Extention of patent term
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.